T cell depletion by polyclonal antithymocyte globulins (ATG) has been used for many years in both organ and hematopoietic cell transplantation as an induction and rejection therapy. Nevertheless, its use remains largely empirical and many clinical questions, such as the determination of an individualized dose, therapeutic relevance of nondepletive effects, or prediction of long-term effects, are still unresolved. This review evaluates the evidence-based knowledge and the uncertainties concerning ATG, and suggests perspectives and opportunities for modern use of this old drug.

中文翻译：

---

抗胸腺细胞球蛋白：是时候重新考虑将其用于肾脏移植了吗？

通过多克隆抗胸腺细胞球蛋白（ATG）清除T细胞已在器官和造血细胞移植中用作诱导和排斥疗法已有多年历史了。然而，它的使用在很大程度上仍是经验性的，许多临床问题，例如确定个体化剂量，非消耗性作用的治疗相关性或长期作用的预测仍未解决。这篇综述评估了有关ATG的循证知识和不确定性，并提出了现代使用这种旧药物的观点和机会。